Photocure receives prestigious Innovation Prize from the Norwegian Cancer Society: Recognition for Groundbreaking Contributions in Bladder Cancer Diagnostics
Oslo, 28 November 2025 – Photocure is honored to announce that we have been awarded the 2025 Innovation Prize from Kreftforeningen, the Norwegian Cancer Society. The prize provides recognition of our commitment to advancing cancer diagnostics and improving patient outcomes. The award, accompanied by a prize of 300,000 NOK, was presented yesterday, during the 10th anniversary celebration of Oslo Cancer Cluster Innovation Park, following rigorous evaluation by a committee appointed by the Norwegian Cancer Society.
The committee considered several criteria, including innovative capacity, documented positive impact for cancer patients, and national or international recognition. During the award ceremony they emphasized how Photocure had established itself as a leading player in Europe and the United States in the field of bladder cancer, bringing products to market and continuing to drive innovation through research and development. The proven benefit to the patient was a key factor in the committee’s decision.
“We are immensely proud that our ongoing innovative work in bladder cancer diagnostics has been recognized on such a prominent platform. As advancements in pharmaceutical therapies for bladder cancer – including immune and gene therapies – continue to transform patient care, the need for precise diagnostics becomes even more critical. Photocure remains dedicated to delivering innovative solutions that help select the right treatment for each patient, and monitor for relapse and treatment response, and ultimately, improve outcomes in uro-oncology,” said Anders Neijber, Chief Medical Officer at Photocure.
“Building on our success and expertise, we aim to create a suite of complementary precision diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare community. Currently, we are collaborating with an AI expert company to develop the next-generation AI-enabled blue light cystoscopy,” said Dan Schneider, President & Chief Executive Officer of Photocure.
Receiving the Cancer Society Innovation Prize is a testament to the continuing dedication of the entire Photocure team, as well as our ongoing collaborations with partners in research, healthcare, and technology. We extend our gratitude to the Norwegian Cancer Society and the selection committee for this recognition, and we reaffirm our commitment to driving progress in precision diagnostics for the benefit of cancer patients worldwide.
Kristine Young-Halvorsen, Clinical Development and Medical Science Director, accepting the Innovation Prize on behalf of Photocure – Oslo Cancer Cluster Innovation Park, 27 November 2025